Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (e+)” rating reiterated by Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

FDMT has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Chardan Capital decreased their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday, May 9th. Bank of America decreased their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a report on Monday, March 10th. The Goldman Sachs Group decreased their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Barclays decreased their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.56.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $3.84 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $28.93. The company has a market cap of $177.91 million, a PE ratio of -1.21 and a beta of 2.84. The business has a 50-day simple moving average of $3.70 and a two-hundred day simple moving average of $4.31.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FDMT. Rhumbline Advisers increased its position in shares of 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after buying an additional 3,675 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $111,000 after buying an additional 10,000 shares in the last quarter. M&T Bank Corp increased its position in shares of 4D Molecular Therapeutics by 98.9% in the fourth quarter. M&T Bank Corp now owns 37,487 shares of the company’s stock valued at $209,000 after buying an additional 18,639 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $629,000. Finally, PNC Financial Services Group Inc. increased its position in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.